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A B S T R A C T
Objectives: Few studies on human papillomavirus (HPV) have been conducted in Mongolia. This study was
performed to evaluate the prevalent HPV genotypes and their associations with cytology and
demographic and behavioral characteristics in Mongolian women with cervical abnormalities.
Methods: Exfoliated cell samples of 100 women who had a previous history of cervical abnormality were
collected. Cytological interpretation was conducted microscopically and HPV genotyping was performed
using the Roche Linear Array test. Study questionnaires were completed.
Results: Overall, 25 HPV genotypes were detected in 47% of participants, and the most prevalent were HPV
16, 52, 58, and 33. Cytological examination revealed 12% of participants had atypical squamous cells of
undetermined signiﬁcance (ASC-US), 8% had low-grade squamous intraepithelial lesions (LSIL), 7% had
high-grade squamous intraepithelial lesions (HSIL), and 14% had squamous cell carcinoma (SCC), while
59% of women had a normal cytology. HPV 16 was the most common type among women with a normal
cytology and cervical cancer. However, women with cervical abnormalities including LSIL and HSIL were
predominantly infected with HPV 52. Moreover, women aged <35 years had a signiﬁcantly higher risk of
HPV infection than those in the other age groups (p < 0.05).
Conclusions: The prevalent trend of HPV genotypes observed in this cohort differs from that reported
previously in Mongolia. These data may contribute to developing an effective strategy for cervical cancer
prevention in Mongolia.
© 2018 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Mongolia is a landlocked country with a total population of
three million. About two-thirds of the population live in the capital
city Ulaanbaatar (Pezzulo et al., 2017); remote areas are sparsely
populated. Mongolia has undergone signiﬁcant socioeconomic
changes accompanied by an unstable government and poor
systemic policy. Thus, a large number of the population has
migrated abroad over the last two decades (Tsilaajav et al., 2013;
Kohrt et al., 2004).* Corresponding author.
E-mail addresses: batchimeg.ts@mnums.edu.mn (B. Tsedenbal),
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1201-9712/© 2018 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Cervical cancer is the fourth most common cancer in women
and the seventh most common cancer overall worldwide.
Compared with Japan and other countries, Mongolia has one of
the highest age-adjusted cervical cancer rates in Asia (Organization
WH, 2014). The current situation in Mongolia indicates that
cervical cancer is the fourth most common cancer in the overall
population and the second most common cancer in women (Ferlay
et al., 2013). According to statistical data for 2015, cervical cancer
morbidity and mortality rates were 29.8 per 100 000 women and
13.6 per 100 000 women, respectively; 51.1% of patients were
diagnosed in the late stage and the 5-year survival rate was
estimated as 44.2% (National Center for Cancer, 2015).
Cervical screening systems are becoming more complex. The
conventional Papanicolaou (Pap) test was a major leap forward in
cervical cancer screening and continues to be used efﬁciently in
many countries. However, the liquid-based cytology test has
increased sensitivity and speciﬁcity compared with the Pap testciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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test for human papillomavirus (HPV), which has a high sensitivity
(>90%) and high negative predictive value compared to liquid-
based cytology and the Pap test, is now recommended by the
World Health Organization (WHO) for cervical cancer screening.
HPV infection is the leading cause of cervical cancer progression
and is sexually transmitted (Castellsagué, 2008). HPV infection can
occur at the beginning of a woman’s sexual life and take several
decades to advance into cervical cancer (Franceschi et al., 2006;
Woodman et al., 2007). However, most HPV infections are
transient and only persistent HPV infections, particularly those
with high-risk HPV (HR-HPV) genotypes, progress into high-grade
lesions or cancer. Individuals with low-risk HPV (LR-HPV)
genotypes are likely to develop genital warts. About 15 HPV
genotypes (16,18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82)
have been classiﬁed as having high oncogenic potential among
>100 HPV genotypes (Muñoz et al., 2003).
Since 2012, HPV DNA testing has played an important role in the
investigation of abnormal cytology ﬁndings to clarify risk types.
Indeed, highly developed countries have included HPV DNA testing
as a part of their triage system in guidelines for the early detection
of cervical cancer (Saslow et al., 2002). In 2011, the Mongolian
Ministry of Health approved clinical guidelines for a uterine
cervical cancer prevention program for women with the target age
of 30–60 years. Since 2012, a uterine cervical cancer screening
program has been implemented in Mongolia for women in the
target age group, which generally consists of a Pap test every 3
years (Chimeddamba et al., 2015; Ministry of Health Mongolia,
2007). Unfortunately, liquid-based cytology and HPV tests are not
accessible because of their high costs. Moreover, data on HPV
prevalence and the type distribution in Mongolia are outdated and
scarce. According to a 2008 study, HPV 16 was the most common
type (54%) among Mongolian women, followed by HPV 58, 18, and
33 (Dondog et al., 2008). Recently, many studies on the
implementation of vaccination for HPV infections with the aim
of preventing cervical lesions related to HPV infection or repeated
infection have been started. The Mongolian Ministry of Health and
the Millennium Challenge Corporation (Washington DC, USA)
organized a pilot HPV vaccine introduction program for schoolgirls
aged 11–15 years in 2012. However, concerns about the side effects
of the HPV vaccines led to the interruption of the pilot program in
the same year (Toh et al., 2017).
The primary aim of this study was to determine the most
prevalent HPV genotypes and their associations with abnormal
cervical cytology in Mongolian women. It was also sought to
analyze the relationships between HPV infection and cervical
abnormalities, demographic data, and behavioral changes. The
results of this pilot study may contribute to future approaches for
cervical cancer screening and HPV prevention and vaccination in
Mongolia.
Methods
Study population and sample collection
This was a hospital-based, cross-sectional study involving 100
women who visited the gynecological outpatient clinic of the
National Center for Cancer in Mongolia during March to May 2017.
Women aged 18–65 years (mean  standard deviation 45 10
years) who had a previous history of cervical abnormalities and
were attending a gynecological examination in order to conﬁrm
whether there was an abnormality or not were eligible for this
study. However, pregnant women, women who had received
radiation therapy or a hysterectomy, and women with any mental
illness/disease history who could not make decisions for them-
selves were excluded from this study. All participants signed aninformed consent form after being provided with an explanation of
the study purpose. They also answered a socioeconomic back-
ground questionnaire. Women with an abnormal cytology classi-
ﬁed as high-grade squamous intraepithelial lesion (HSIL) or more
were advised to undergo colposcopy and/or biopsy; however,
women with atypical squamous cells of undetermined signiﬁcance
(ASC-US) or low-grade squamous intraepithelial lesions (LSIL)
were advised to undergo a repeat cervical smear test after 6
months; all patients were treated in accordance with the guide-
lines for management standardized by the Ministry of Health in
Mongolia. Cervical samples were collected by a gynecologist using
Cervex-Brush Combi (Rovers Medical Devices B.V., Oss, The
Netherlands). The brush head was directly suspended in a TACAS
GYN Vial (Medical & Biological Laboratories Co., Ltd, Tokyo, Japan)
and kept in a refrigerator at 4 C until transported to the laboratory
at Gunma University.
Ethical considerations
This study was conducted under cooperation between the
Mongolian National University of Medical Sciences, Mongolia and
Gunma University, Japan. The study was approved by the ethics
and research committees of the Graduate School of Health
Sciences, Gunma University (number 2016/020) and the Mongo-
lian National University of Medical Sciences (number B/191). Study
approval was also obtained from the Ethics Review Board of the
Ministry of Health, Mongolia.
HPV DNA genotyping and cytological examination of samples
HPV DNA testing was performed using exfoliated cervical cells
from the TACAS GYN Vial before any procedure to minimize
contamination. The Linear Array HPV Genotyping Test (Roche
Molecular Systems, Branchburg, NJ, USA) was used to detect the 37
HPV genotypes in this study. Three speciﬁc kits (the Amplicor
Linear Array Extraction Kit, Linear Array HPV Genotyping Kit, and
Linear Array Detection Kit) were used for the following processes:
specimen preparation, DNA extraction, PCR ampliﬁcation of target
DNA using HPV primers, and hybridization of the ampliﬁed
products to oligonucleotide probes and detection of the probe-
bound ampliﬁed products by colorimetric determination accord-
ing to the manufacturer’s instructions (Jamison et al., 2009). Final
color precipitation of testing strips allowed for manual reading of
genotype detection by comparison with a reference card. Residual
cell samples in the vial were manually processed according to the
protocol of the TACAS system. Processed cytological smears were
dyed with Papanicolaou stain and interpreted by senior and junior
cytopathologists according to the Pap test and Bethesda System
2014 (Nayar and Wilbur, 2015).
Statistical analysis
Statistical analyses were conducted using IBM SPSS Statistics
version 23.0 (IBM Corp., Armonk, NY, USA). Statistical means, p-
values, and odds ratios (OR) were determined. Associations
between demographic/behavioral characteristics and HPV positiv-
ity and cytological abnormalities were analyzed by logistic
regression analysis. All tests were considered statistically signiﬁ-
cant at the level of p < 0.05.
Results
Cytological diagnosis of all participants
Among the 100 women who participated in this study, the Pap
test revealed that 12% had ASC-US, 8% had LSIL, 7% had HSIL, and
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participants had normal cytological results (negative for intra-
epithelial lesion or malignancy, NILM) (Table 1).
Overall HPV prevalence and type distribution
Overall, HPV DNA was detected in 47% (47/100) of participants,
of whom 32% were infected with single HPV infections and 68%
were infected with multiple HPV infections. Twenty-ﬁve geno-
types were detected including HPV 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 53, 70, 73, 82, 42, 54, 55, 61, 62, 81, 83, and CP6108
(Figure 1). The most prevalent HR-HPV types were 16 (21%, 21/100)
and 52 (14%, 14/100), followed by 58 (6%, 6/100), 33 (6%, 6/100),
and 31 (5%, 5/100). HPV 55 (6%, 6/100) and 54 (5%, 5/100) were
dominant among LR-HPV types. The other genotypes had
frequencies of 4% or less.
HPV prevalence according to cytological abnormalities
The prevalence of HPV-positive women among those with
normal cervical smears was 32% (15/47), whereas the prevalence
among women with ASC-US, LSIL, HSIL, and SCC were 13% (6/47),
17% (8/47), 13% (6/47), and 26% (12/47), respectively (Table 2).
Single LR-HPV types were detected in 13.3% (2/15) of women with a
normal cytology and 16.6% (1/6) of women with ASC-US, while
there was no detection in women with LSIL, HSIL, or SCC. Single HR-
HPV types were detected in 20% (3/15) of women with a normal
cytology, 16.6% (1/6) of women with ASC-US, 33.3% (2/6) of women
with HSIL, and 50% (6/12) of women with SCC. The proportions of
multiple HPV infections detected in women with cytological NILM,
ASC-US, LSIL, HSIL, and SCC were 66.7% (10/15), 66.7% (4/6), 100%
(8/8), 66.7% (4/6), and 50% (6/12), respectively (Table 2).
Relevant HPV genotypes within different cytological abnormalities
The prevalence and distribution of the most frequent HPV
genotypes among cytological abnormalities are shown in Figure 2.
HPV 16 was the most prevalent genotype detected in women with
SCC, followed by HPV 52, 33, 54, and 31. HPV 52 was the most
common genotype in women with LSIL and HSIL, followed by HPV
58 and 59 in LSIL and HPV 33, 58, and 82 in HSIL. HPV 16, 52, and 55
were the most common genotypes in women with ASC-US, while
women with a normal cytology were frequently infected with HPV
16 and 45.
Demographic and behavioral risk factors of women with HPV infection
and cytological abnormalities
Multivariable analyses of demographic and behavioral risk
factors for HPV DNA positivity and cytological abnormalities are
summarized in Table 3. Women aged between 25 and 34 years
were 4.1 times (95% conﬁdence interval 1.0–16.8) as likely to be
HPV DNA-positive as women aged 55 years (p < 0.05). OtherTable 1
Representation of cytological ﬁndings among all participants (n = 100).
Cytological diagnosis n (%)
NILM 59 (59)
ASC-US 12 (12)
LSIL 8 (8)
HSIL 7 (7)
SCC 14 (14)
NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous
cells of undetermined signiﬁcance; LSIL, low-grade squamous intraepithelial
lesion; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell
carcinoma.variables and risk factors within cytological abnormalities showed
no statistically signiﬁcant differences.
Discussion
Considering the current wide range of international communi-
cation due to travel or immigration, changes in HPV genotype
distribution in certain populations are highly probable. The current
study appears to be the ﬁrst to investigate the most prevalent HPV
genotypes and their relationships with cervical abnormalities
among Mongolian women.
HPV DNA was detected in 47% of study participants, and more
women had multiple infections (68%) than single infections (32%).
A previous study conducted in 2008 showed that overall HPV DNA
prevalence was 35% among 800 women in Ulaanbaatar city
(Dondog et al., 2008). The increased HPV DNA prevalence in this
study may be attributed to the study cohort, as women who had a
previous history of abnormal cytology were analyzed in this study.
The present study also found HPV 16, 52, 58, 33, and 31 to be the
dominant HR-HPV types, and HPV 55 and 54 to be the dominant
LR-HPV types distributed among Mongolian women. These results
are similar to those reported from Asian countries such as Japan
(HPV 16, 18, 52, and 58) and South Korea (HPV 16, 58, 33, and 52)
(Onuki et al., 2009; Takehara et al., 2011; So et al., 2016). Previous
studies indicated that HPV 16 was the dominant genotype,
followed by HPV 58, 18, 33, and 45 (Dondog et al., 2008;
Chimeddorj et al., 2008). However, the current study revealed a
high prevalence of HPV 52 and low prevalence of HPV 18 among
Mongolian women. This minor change in HPV infections suggests
that the small sample size of this study could have led to a possible
bias, or that study participants with cervical abnormalities may
have affected this distribution in the present study. Furthermore,
the previous HPV studies in this country, which has a small
population, were performed almost 10 years ago. Increased
migration of Mongolians throughout the world, especially to
Asian countries, and the poor socioeconomic conditions over the
last two decades, along with the development of tests, could
explain this distribution difference in HPV infections (Rousseau
et al., 2001). Thus, we consider it crucial that new research be
performed with increased numbers of study participants and with
increased reporting of demographic characteristics and risk factors
related to HPV types.
The distribution of single and multiple infections was evaluated
in participants with a normal cytology and ASC-US (Table 2). The
overall multiple infection rate for HPV DNA positivity in LSIL was
high (100%) in this study, and was similar to a study in a Latino
cohort (Zhou et al., 2014). HPV 52, 58, 59, and 16 were the most
common types detected in LSIL. The multiple infection rate (66.7%)
for HPV DNA positivity was also higher in HSIL than the single
infection rate (33.3%). HPV genotypes commonly detected in HSIL
were 52, 16, and 33. However, there was no difference in single and
multiple infection rates in participants with SCC. The most
common HPV genotypes detected in SCC were HPV 16, 52, 33,
and 31, which differs from the previous study in Mongolia (HPV 16,
35, 31, and 58) (Dondog et al., 2008). These ﬁndings suggest that
only persistent HPV genotypes lead to cervical dysplasia, regard-
less of single or multiple infections. Since the study identiﬁed
probable high risk HPV types circulating in this country, it is
important to formulate an appropriate, targeted strategy to
prevent HPV infection in each region.
According to the demographic and behavioral risk factors
questionnaire, Mongolian women aged <35 years were more likely
to have HPV DNA positivity than women in the other age groups.
This ﬁnding supports results from a previous study that showed
HPV infection to be highest in women aged <25 years in Mongolia
(Dondog et al., 2008). HPV infections generally peak at a young age,
Figure 1. Distribution of HPV genotypes detected in overall participants. HPV, human papillomavirus; HR-HPV, high-risk HPV; LR-HPV, low-risk HPV.
Table 2
Frequency of HPV DNA positivity results according to cytological abnormalities (n = 47).
Cytological diagnosis HPV DNA positivity (%) Single infection (%) Multiple infections (%)
LR-HPV HR-HPV
NILM 15 (32) 2 (13.3) 3 (20) 10 (66.7)
ASC-US 6 (13) 1 (16.6) 1 (16.6) 4 (66.7)
LSIL 8 (17) 0 (0) 0 (0) 8 (100)
HSIL 6 (13) 0 (0) 2 (33.3) 4 (66.7)
SCC 12 (26) 0 (0) 6 (50) 6 (50)
Total 47 (100) 3 (6.4) 12 (25.5) 32 (68.1)
HPV, human papillomavirus; LR-HPV, low-risk HPV; HR-HPV, high-risk HPV; NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of
undetermined signiﬁcance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell carcinoma.
Figure 2. Most frequent HPV genotypes according to cytological abnormality. HPV, human papillomavirus; NILM, negative for intraepithelial lesion or malignancy; ASC-US,
atypical squamous cells of undetermined signiﬁcance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; SCC, squamous cell
carcinoma.
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most infections clear within a few years (Franco and Harper, 2005;
Wang et al., 2015). Furthermore, no signiﬁcant difference in
cytological ﬁndings according to age group was observed. This
result can be explained by the fact that the number of women
included in this study was small and HPV DNA testing is more
sensitive than cytology testing. Furthermore, this ﬁnding suggests
that the target age range for the cervical cancer screening program
and primary prevention system should be reconsidered for the
young generation in Mongolia. Other factors including residency,
relationship status, contraceptive use, age at ﬁrst sexual inter-
course, number of lifetime sexual partners, and history of induced
abortion were not signiﬁcantly associated with HPV DNA positivity
or abnormal cytology results in this study. Moreover, it was not
possible to determine information regarding the exact number of
lifetime sexual partners of the participants’ partners or husbands,
which prevents a complete understanding of the high incidence ofmultiple infection, but not signiﬁcant risk factors of sexual
behavior in participants. Further investigations are required to
clarify these ﬁndings by increasing the sample size and including
information about partners and husbands.
This study has some limitations that must be discussed. First,
the number of study participants was small, and thus the data do
not directly represent the whole population. Second, this was a
cross-sectional study and whether the HPV infections were
transient or persistent remains uncertain due to the absence of
a follow-up system. Although progression to lesion or cancer may
occur several decades after infection, it is not possible to detect
simultaneous or sequential infections with each HPV genotype and
potential combinatorial effects on cytological characteristics.
Third, there is a need for new research on demographic
characteristics and risk factors associated with HPV types,
increasing the number of subjects in the study population. Despite
these limitations, the strengths of this study include the use of the
Table 3
Multivariable analyses of demographic and behavioral risk factors for HPV DNA positivity and abnormal cervical cytology (n = 100).a
Risk factor Total
n (%)
HPV DNA positivityb Abnormal cytologyc
Positive
n (%)
OR (95% CI) p-Value Positive
n (%)
OR (95% CI) p-Value
Residency
Ulaanbaatar cityd 61 (61) 27 (44) 0.5 (0.1–1.4) 0.2 23 (38) 0.6 (0.2–1.6) 0.35
Country 39 (39) 20 (51) – 18 (46) –
Age group
25–34 years 19 (19) 12 (63) 4.1 (1.0–17) 0.04 9 (47) 1.8 (0.5–6.7) 0.36
35–44 years 27 (27) 11 (41) 1.2 (0.3–4.4) 0.74 10 (37) 0.9 (0.3–3.1) 0.96
45–54 years 29 (29) 15 (52) 1.6 (0.4–5.8) 0.40 12 (41) 1 (0.3–3.1) 0.94
55 years 25 (25) 9 (36) – 10 (40) –
Relationship status
Single 11 (11) 6 (55) 1.4 (0.2–10.8) 0.69 9 (82) –
Married 77 (77) 35 (45) 0.8 (0.2–3.1) 0.75 27 (35) 6.3 (0.9–42.7) 0.06
Divorced/widowed 12 (12) 6 (50) – 5 (42) 0.7 (0.2–2.6) 0.65
Contraceptive use
Yes 45 (45) 22 (49) 0.9 (0.3–2.6) 0.95 17 (38) 0.6 (0.2–1.5) 0.34
No 55 (55) 25 (45) – 24 (44) –
Age at ﬁrst sexual intercourse
<20 years 33 (33) 15(45) 1.9 (0.3–9.9) 0.40 13 (39) 1.7 (0.3–7.7) 0.45
20–24 years 55 (55) 28 (51) 2.2 (0.5–9.4) 0.28 24 (44) 1.6 (0.4–6.4) 0.45
25 years 12 (12) 4 (33) – 4 (33) –
Lifetime number of sexual partners
1 47 (47) 25 (53) 2.2 (0.8–5.8) 0.08 21 (45) 1.3 (0.5–2.9) 0.53
2 53 (53) 22 (42) – 20 (38) –
Induced abortion
None 26 (26) 12 (46) 0.9 (0.3–2.9) 0.99 13 (50) 2.1 (0.7–5.7) 0.14
1 28 (28) 14 (50) 1.2 (0.4–3.7) 0.70 12 (43) 1.6 (0.6–4.3) 0.33
2 44 (44) 19 (43) – 14 (32) –
HPV, human papillomavirus; OR, odds ratio; CI, conﬁdence interval.
a Adjustment for age did not substantially change the ﬁndings.
b HPV DNA positivity includes high- and low-risk HPV infections.
c Abnormal cytology includes: ASC-US, atypical squamous cells of undetermined signiﬁcance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous
intraepithelial lesion; SCC, squamous cell carcinoma.
d Ulaanbaatar city indicates the capital city of Mongolia.
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genotyping test, which were repeated for inconclusive results.
Furthermore, this study described the probable relationship
between HPV types and demographic and behavioral risk factors.
In conclusion, this study revealed the prevalence of HPV
genotypes among Mongolian women and the frequency in cervical
abnormalities. Even with the small population size, these data on
the most prevalent HPV genotypes could form the basis for future
studies and may contribute to formulating prevention and
vaccination programs and a follow-up system for HPV infection
in Mongolia.
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